Loading...
Symbols:
Loading...
Symbols:
Genzyme Corp. (GENZ)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Genzyme Corp. (GENZ)
71 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on GENZ
- SA Editor Miriam Metzinger(19)
- SA Editor Joan Wickham(6)
- Mike Havrilla(5)
- A. Reza Saadat(4)
- Don Dion(4)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(571)
- SA Editor Eli Hoffmann(386)
- SA Editor Joan Wickham(145)
- Tom Lydon(131)
- Zacks.com (127)
Most commented on authors
- SA Editor Joan Wickham(25)
- Ketan Desai (13)
- Keith Robison(11)
- Michael Steinberg (11)
- Freund Investing(8)
- Three-Month, Updated FDA Decision Calendar
- Best and Worst S&P 500 Stocks Since the 11/20 Closing Low
- What Are Some of the Best Hedge Fund Managers Doing?
- Regenerative Medicine: Big Pharma's Next Frontier
- Biotech ETFs a Rare Safe Haven
- Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal
- Genzyme and Osiris Get Together on Stem Cells
- Cosmetic and Reconstructive Medicine ETF Outpaces Healthcare Sector
- FDA Action Before Year End
- Industry Profile: Cosmetic and Reconstructive Medicine
- Some Good News in Biotech
- Biotech Names With Big Potential
- Time for Biotech? - Fast Money Recap (07/29/08)
- Biotech Bucks the Market Trend
- PTC and Genzyme in $437M Gene Therapy Deal
- Big Biotech Booms But IBB Falls Flat
- In Tech We Trust - Fast Money Recap (6/20/08)
- FDA Stings Pharma, Big and Small
- Biotech Fundamentals Still Look Strong
- 10 Biotechs in Stem Cells that Could Profit Under the Democrats
- Will M&A Activity Boost PowerShares Dynamic Biotech & Genome ETF?
- Biotech in Review: Investments in China Drug Development
- Isis Pharmaceuticals Panic Overdone
- Genzyme To Build $90 Million R&D Center in Beijing
- Fast Money Recap, 4/1/08: Gold Takes the Elevator
- Fast Money Recap, 3/31/08: Big Spender Lehman
- Pfizer Should Buy Amgen or Wyeth - Credit Suisse
- Under The Radar News - Friday
- A Long List of Possible Shorts
- Isis-Genzyme: Deal of the Year?
- A Volatile January for Financials, Healthcare
- Wal-Mart's Guidance Shows No Sign of Slow-Down, Good for Investors
- Pharma, Biotech Present Great Investment Opportunities in 2008
- A Win-Win for Isis, Genzyme in Cholesterol Drug Deal
- VMware, Isis Pharma: Avoid Emotion in Market Swings
- Wall Street Breakfast: Must-Know News
- NASDAQ -100 Eyes August Lows
- China’s Gene Therapy Cancer Drugs: Slow Acceptance of Great Science
- The Bells Toll Less for the Biotechs
- Biotech Fund IBB May Ride the M&A Frenzy, but It's Still Wildly Volatile
- Icahn's Hedge Fund Has New Stakes In Genzyme and Childrens Place, Among Others
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »